Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
Cancer of unknown primary has a dismal prognosis, especially following failure of platinum-based chemotherapy. 10-20% of patients have a high tumor mutational burden (TMB), which predicts response to immunotherapy in many cancer types. In this prospective, non-randomized, open-label, multicenter Pha...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
24 October 2023
|
| In: |
Nature Communications
Year: 2023, Jahrgang: 14, Pages: 1-21 |
| ISSN: | 2041-1723 |
| DOI: | 10.1038/s41467-023-42400-5 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41467-023-42400-5 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41467-023-42400-5 
|
| Verfasserangaben: | Maria Pouyiourou, Bianca N. Kraft, Timothy Wohlfromm, Michael Stahl, Boris Kubuschok, Harald Löffler, Ulrich T. Hacker, Gerdt Hübner, Lena Weiss, Michael Bitzer, Thomas Ernst, Philipp Schütt, Thomas Hielscher, Stefan Delorme, Martina Kirchner, Daniel Kazdal, Markus Ball, Klaus Kluck, Albrecht Stenzinger, Tilmann Bochtler & Alwin Krämer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1889487791 | ||
| 003 | DE-627 | ||
| 005 | 20250325051144.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240522s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-023-42400-5 |2 doi | |
| 035 | |a (DE-627)1889487791 | ||
| 035 | |a (DE-599)KXP1889487791 | ||
| 035 | |a (OCoLC)1443678859 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pouyiourou, Maria |e VerfasserIn |0 (DE-588)1245540866 |0 (DE-627)1777245079 |4 aut | |
| 245 | 1 | 0 | |a Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary |b a phase II trial |c Maria Pouyiourou, Bianca N. Kraft, Timothy Wohlfromm, Michael Stahl, Boris Kubuschok, Harald Löffler, Ulrich T. Hacker, Gerdt Hübner, Lena Weiss, Michael Bitzer, Thomas Ernst, Philipp Schütt, Thomas Hielscher, Stefan Delorme, Martina Kirchner, Daniel Kazdal, Markus Ball, Klaus Kluck, Albrecht Stenzinger, Tilmann Bochtler & Alwin Krämer |
| 264 | 1 | |c 24 October 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 21 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.05.2024 | ||
| 520 | |a Cancer of unknown primary has a dismal prognosis, especially following failure of platinum-based chemotherapy. 10-20% of patients have a high tumor mutational burden (TMB), which predicts response to immunotherapy in many cancer types. In this prospective, non-randomized, open-label, multicenter Phase II trial (EudraCT 2018-004562-33; NCT04131621), patients relapsed or refractory after platinum-based chemotherapy received nivolumab and ipilimumab following TMBhigh vs. TMBlow stratification. Progression-free survival (PFS) represented the primary endpoint; overall survival (OS), response rates, duration of clinical benefit and safety were the secondary endpoints. The trial was prematurely terminated in March 2021 before reaching the preplanned sample size (n = 194). Among 31 evaluable patients, 16% had a high TMB ( > 12 mutations/Mb). Overall response rate was 16% (95% CI 6-34%), with 7.7% (95% CI 1-25%) vs. 60% (95% CI 15-95%) in TMBlow and TMBhigh, respectively. Although the primary endpoint was not met, high TMB was associated with better median PFS (18.3 vs. 2.4 months) and OS (18.3 vs. 3.6 months). Severe immune-related adverse events were reported in 29% of cases. Assessing on-treatment dynamics of circulating tumor DNA using combined targeted hotspot mutation and shallow whole genome sequencing as part of a predefined exploratory analysis identified patients benefiting from immunotherapy irrespective of initial radiologic response. | ||
| 650 | 4 | |a Cancer of unknown primary | |
| 650 | 4 | |a Molecular medicine | |
| 650 | 4 | |a Phase II trials | |
| 650 | 4 | |a Predictive markers | |
| 700 | 1 | |a Kraft, Bianca |d 1981- |e VerfasserIn |0 (DE-588)1011974614 |0 (DE-627)660882612 |0 (DE-576)344709175 |4 aut | |
| 700 | 1 | |a Wohlfromm, Timothy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stahl, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kubuschok, Boris |e VerfasserIn |4 aut | |
| 700 | 1 | |a Löffler, Harald |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hacker, Ulrich T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hübner, Gerdt |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weiss, Lena |e VerfasserIn |4 aut | |
| 700 | 1 | |8 1\p |a Bitzer, Michael |d 1966- |e VerfasserIn |0 (DE-588)129176877 |0 (DE-627)390358797 |0 (DE-576)188104933 |4 aut | |
| 700 | 1 | |8 2\p |a Ernst, Thomas |d 1976- |e VerfasserIn |0 (DE-588)129357685 |0 (DE-627)393983285 |0 (DE-576)297617737 |4 aut | |
| 700 | 1 | |a Schütt, Philipp |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hielscher, Thomas |e VerfasserIn |0 (DE-588)1159594791 |0 (DE-627)1022977768 |0 (DE-576)50506068X |4 aut | |
| 700 | 1 | |a Delorme, Stefan |e VerfasserIn |0 (DE-588)105842808X |0 (DE-627)796879761 |0 (DE-576)179470140 |4 aut | |
| 700 | 1 | |a Kirchner, Martina |d 1973- |e VerfasserIn |0 (DE-588)1017178976 |0 (DE-627)676266363 |0 (DE-576)353239747 |4 aut | |
| 700 | 1 | |a Kazdal, Daniel |d 1983- |e VerfasserIn |0 (DE-588)114929650X |0 (DE-627)1009614088 |0 (DE-576)496635867 |4 aut | |
| 700 | 1 | |a Ball, Markus |e VerfasserIn |0 (DE-588)1057908746 |0 (DE-627)795401108 |0 (DE-576)41391738X |4 aut | |
| 700 | 1 | |a Kluck, Klaus |e VerfasserIn |0 (DE-588)122679940X |0 (DE-627)1747876127 |4 aut | |
| 700 | 1 | |a Stenzinger, Albrecht |e VerfasserIn |0 (DE-588)139606106 |0 (DE-627)703395238 |0 (DE-576)312432755 |4 aut | |
| 700 | 1 | |a Bochtler, Tilmann |d 1975- |e VerfasserIn |0 (DE-588)128398957 |0 (DE-627)372639925 |0 (DE-576)187323909 |4 aut | |
| 700 | 1 | |a Krämer, Alwin |e VerfasserIn |0 (DE-588)1067780025 |0 (DE-627)819183431 |0 (DE-576)426900820 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature Communications |d [London] : Springer Nature, 2010 |g 14(2023), Artikel-ID 6761, Seite 1-21 |h Online-Ressource |w (DE-627)626457688 |w (DE-600)2553671-0 |w (DE-576)331555905 |x 2041-1723 |7 nnas |a Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary a phase II trial |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g elocationid:6761 |g pages:1-21 |g extent:21 |a Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary a phase II trial |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41467-023-42400-5 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |7 1 |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41467-023-42400-5 |x Verlag |z lizenzpflichtig |3 Volltext |7 1 |
| 883 | |8 1\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 2\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20240522 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 1067780025 |a Krämer, Alwin |m 1067780025:Krämer, Alwin |d 910000 |d 910100 |e 910000PK1067780025 |e 910100PK1067780025 |k 0/910000/ |k 1/910000/910100/ |p 21 |y j | ||
| 998 | |g 128398957 |a Bochtler, Tilmann |m 128398957:Bochtler, Tilmann |d 910000 |d 910100 |d 50000 |e 910000PB128398957 |e 910100PB128398957 |e 50000PB128398957 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 20 | ||
| 998 | |g 139606106 |a Stenzinger, Albrecht |m 139606106:Stenzinger, Albrecht |d 910000 |d 912000 |d 50000 |e 910000PS139606106 |e 912000PS139606106 |e 50000PS139606106 |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 19 | ||
| 998 | |g 122679940X |a Kluck, Klaus |m 122679940X:Kluck, Klaus |d 910000 |d 912000 |d 50000 |e 910000PK122679940X |e 912000PK122679940X |e 50000PK122679940X |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 18 | ||
| 998 | |g 1057908746 |a Ball, Markus |m 1057908746:Ball, Markus |d 910000 |d 912000 |d 50000 |e 910000PB1057908746 |e 912000PB1057908746 |e 50000PB1057908746 |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 17 | ||
| 998 | |g 114929650X |a Kazdal, Daniel |m 114929650X:Kazdal, Daniel |d 910000 |d 912000 |d 50000 |e 910000PK114929650X |e 912000PK114929650X |e 50000PK114929650X |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 16 | ||
| 998 | |g 1017178976 |a Kirchner, Martina |m 1017178976:Kirchner, Martina |d 910000 |d 912000 |d 50000 |e 910000PK1017178976 |e 912000PK1017178976 |e 50000PK1017178976 |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 15 | ||
| 998 | |g 105842808X |a Delorme, Stefan |m 105842808X:Delorme, Stefan |d 50000 |e 50000PD105842808X |k 0/50000/ |p 14 | ||
| 998 | |g 1159594791 |a Hielscher, Thomas |m 1159594791:Hielscher, Thomas |d 50000 |e 50000PH1159594791 |k 0/50000/ |p 13 | ||
| 998 | |g 1011974614 |a Kraft, Bianca |m 1011974614:Kraft, Bianca |d 910000 |d 910100 |e 910000PK1011974614 |e 910100PK1011974614 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 1245540866 |a Pouyiourou, Maria |m 1245540866:Pouyiourou, Maria |d 910000 |d 910100 |e 910000PP1245540866 |e 910100PP1245540866 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1889487791 |e 4527047728 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary","subtitle":"a phase II trial","title_sort":"Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Maria Pouyiourou, Bianca N. Kraft, Timothy Wohlfromm, Michael Stahl, Boris Kubuschok, Harald Löffler, Ulrich T. Hacker, Gerdt Hübner, Lena Weiss, Michael Bitzer, Thomas Ernst, Philipp Schütt, Thomas Hielscher, Stefan Delorme, Martina Kirchner, Daniel Kazdal, Markus Ball, Klaus Kluck, Albrecht Stenzinger, Tilmann Bochtler & Alwin Krämer"]},"origin":[{"dateIssuedDisp":"24 October 2023","dateIssuedKey":"2023"}],"person":[{"display":"Pouyiourou, Maria","role":"aut","given":"Maria","family":"Pouyiourou"},{"family":"Kraft","display":"Kraft, Bianca","role":"aut","given":"Bianca"},{"display":"Wohlfromm, Timothy","role":"aut","given":"Timothy","family":"Wohlfromm"},{"family":"Stahl","display":"Stahl, Michael","given":"Michael","role":"aut"},{"family":"Kubuschok","display":"Kubuschok, Boris","role":"aut","given":"Boris"},{"family":"Löffler","display":"Löffler, Harald","given":"Harald","role":"aut"},{"family":"Hacker","given":"Ulrich T.","role":"aut","display":"Hacker, Ulrich T."},{"given":"Gerdt","role":"aut","display":"Hübner, Gerdt","family":"Hübner"},{"given":"Lena","role":"aut","display":"Weiss, Lena","family":"Weiss"},{"role":"aut","given":"Michael","display":"Bitzer, Michael","family":"Bitzer"},{"family":"Ernst","role":"aut","given":"Thomas","display":"Ernst, Thomas"},{"display":"Schütt, Philipp","role":"aut","given":"Philipp","family":"Schütt"},{"family":"Hielscher","given":"Thomas","role":"aut","display":"Hielscher, Thomas"},{"display":"Delorme, Stefan","given":"Stefan","role":"aut","family":"Delorme"},{"role":"aut","given":"Martina","display":"Kirchner, Martina","family":"Kirchner"},{"family":"Kazdal","display":"Kazdal, Daniel","role":"aut","given":"Daniel"},{"display":"Ball, Markus","role":"aut","given":"Markus","family":"Ball"},{"family":"Kluck","given":"Klaus","role":"aut","display":"Kluck, Klaus"},{"family":"Stenzinger","role":"aut","given":"Albrecht","display":"Stenzinger, Albrecht"},{"family":"Bochtler","display":"Bochtler, Tilmann","given":"Tilmann","role":"aut"},{"family":"Krämer","given":"Alwin","role":"aut","display":"Krämer, Alwin"}],"language":["eng"],"physDesc":[{"noteIll":"Illustrationen","extent":"21 S."}],"note":["Gesehen am 17.05.2024"],"recId":"1889487791","id":{"eki":["1889487791"],"doi":["10.1038/s41467-023-42400-5"]},"relHost":[{"language":["eng"],"origin":[{"publisher":"Springer Nature ; Nature Publishing Group UK","publisherPlace":"[London] ; [London]","dateIssuedDisp":"[2010]-"}],"pubHistory":["2010-"],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title":"Nature Communications","title_sort":"Nature Communications"}],"part":{"extent":"21","year":"2023","text":"14(2023), Artikel-ID 6761, Seite 1-21","volume":"14","pages":"1-21"},"recId":"626457688","disp":"Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary a phase II trialNature Communications","id":{"zdb":["2553671-0"],"issn":["2041-1723"],"eki":["626457688"]},"note":["Gesehen am 13.06.24"],"physDesc":[{"extent":"Online-Ressource"}]}]} | ||
| SRT | |a POUYIOUROUNIVOLUMABA2420 | ||